Chronic endometritis increases the recurrence of endometrial polyps in premenopausal women after hysteroscopic polypectomy

Endometrial polyps (EPs) represent a common benign gynecological condition that manifests via excessive local hyperplasia of the interstitial and endometrial glands. The prevalence of EPs ranges from 7.8 to 34.9% across different populations [1]. Although the pathogenesis and exact cause of EPs were unknown, chronic inflammation in the endometrium may result in the formation of EPs [2]. The hyaline thickening of vessels was the common morphological vascular alteration of chronic endometritis (CE), which was very similar to the thick-walled vessels of EPs [3]. The increased expression of transforming growth factor-beta 1 (TGF-β1), vascular endothelial growth factor (VEGF), tumor protein P73 (TP73), tumor protein P63 (TP63) and BAX (BCL-2 associated X protein) transcript variant alpha demonstrated the dominance of proliferative and anti-apoptotic activity in CE. This may potentially promote the development and recurrence of EPs [4].

CE involves persistent local inflammation of endometrium, characterized by the presence of plasma cells infiltrating the interstitium [5, 6]. CE is usually asymptomatic or presents only with mild symptoms, such as abnormal uterine bleeding (AUB), pelvic pain, dyspareunia and leucorrhea, as well as infertility and miscarriage, all of which are very similar to the symptoms of EPs [7]. Immunohistochemistry for the plasmacyte marker CD138 is currently the most reliable diagnostic method for CE, which is superior to haematoxylin and eosin (HE) staining and hysteroscopic diagnosis [8‐11]. However, the spontaneous cure rate of CE reported in a randomized clinical trial was as low as only 12.7% [12]. The optimal treatment currently for CE is oral antibiotics [13, 14].

EPs are associated with AUB, infertility and recurrent reproductive failure [1, 2, 15]. Hysteroscopic polypectomy is considered as the gold standard treatment for EPs [15, 16]. Many studies have reported that the recurrence rate of EPs at 12 months after hysteroscopic polypectomy ranged widely from 5.6 to 31.4% [17‐19]. A large number of EPs, endometriosis and previous polypectomy history are found to be independent risk factors for the recurrence of EPs [18, 19]. In addition, late menopause and obesity increase the occurrence of EPs [20]. However, the factors influencing the recurrence potential of EPs after hysteroscopic polypectomy remain rather controversial. Furthermore, the known definite independent risk factors are almost unchangeable, such as the number of EPs and previous polypectomy history, and thus, concealed changeable factors need to be explored. CE was involved in the formation of EPs. Was CE also involved in the recurrence of EPs after hysteroscopic polypectomy?

In the retrospective study, we investigated whether CE increased the recurrence of EPs in premenopausal women after hysteroscopic polypectomy.

In this retrospective cohort study of 233 participants who underwent hysteroscopic polypectomy as treatment for EPs, the recurrence rates of EPs were significantly higher in women with CE than in those without CE at each monitoring stage, i.e., at 3, 6, 9 and 12 months. These findings indicated a harmful role of CE in the recurrence of EPs in premenopausal women after hysteroscopic polypectomy. The HR for EPs recurrence in the EPs with CE cohort compared with the EPs without CE cohort was 3.06, after adjustment for the number of EPs.

Concealed changeable factors for the recurrence of EPs need to be explored, as the known independent risk factors are almost unchangeable, such as the number of EPs and previous polypectomy history [18]. In this study, the overall recurrence rate of EPs in premenopausal women was 14.2% at 12 months after hysteroscopic polypectomy, which is consistent with rates reported in previous studies [17, 22‐24]. Although, after subgroup analysis according to CE, the recurrence rate of EPs in premenopausal women increased to 26.6%, and CE played a harmful role in the recurrence of EPs. To the best of our knowledge, our study is the first to report the effect of CE. Similarly, the recurrence rate of EPs was significantly higher in women with CE than in those without CE at each monitoring stage, i.e., 7.8% versus 1.2% at 3 months, 15.6% versus 4.1% at 6 months, and 21.9% versus 7.1% at 9 months. This may be a possible explanation for the wide range of the EPs recurrence rates (5.6–31.4%) during 1-year follow-up reported before [17‐19]. CE may have been a concealed factor for the recurrence of EPs. The underlying mechanism of the harmful effects of CE is currently unknown. One possible explanation is that the vessel axis of EPs may actually originate from the evolution of vascular changes associated with endometritis [3]. Secondly, the dominance of proliferative and anti-apoptotic activity in CE may result in the formation and recurrence of EPs [4]. TGF-β1, VEGF, TP73 and TP63 were overexpressed in CE. Finally, compared with non-polypoid endometrium, endometrium of EPs and CE had a lower density of NK cells [25]. This may potentially lead to in situ growth and recurrence of EPs after hysteroscopic polypectomy.

CE is a disease involving destruction of the homeostasis between microorganisms in the endometrium and the host immune system. The most common bacterial pathogens causing CE are reported to be Enterobacteriaceae, Enterococcus, Streptococcus, Staphylococcus, Mycoplasma, and Ureaplasma [26]. Similarly, another study found that the most abundant genus in the microbiota of endometrium with CE is non-Lactobacillus [27]. Antibiotics are effective for treating CE [8, 21, 28‐30], as it is caused by bacterial pathogens. Although CE was an independent risk factor for polyp recurrence, unlike unchangeable factors, CE can be changed easily by treatment of antibiotics. The one course cure rate of CE was 72.6% treated with oral doxycycline 200 mg daily for 14 days and 89.8% treated with oral levofloxacin 500 mg and tinidazole 1000 mg daily for 14 days [8, 21].

In the current study, to better evaluate the impact of CE on polyp recurrence, patients with definite external confounding factors for polyp recurrence, including endometriosis and previous polypectomy history, were excluded. Univariate analysis was used to determine the relationship between the recurrence of EPs and its potential risk factors, including age, BMI, polyp size, number of EPs and CE. According to the previous studies [17, 18], polycystic ovary syndrome, infertility, gravidity and parity were not included for analysis. Multiple EPs and CE were associated with the potential recurrence of EPs (P < 0.05). The HR for EPs recurrence in the multiple EPs cohort compared with the solitary EP cohort was 3.02, which is consistent with previous studies, showing a 3.45 HR with a high number of EPs [18]. After adjusting for CE, The HR of EPs number was 2.99, which may truly reflect the impact of the EPs number. Thus, frequent monitoring was needed for multiple polyps after hysteroscopic polypectomy. Simultaneously, the recurrence of EPs was not affected by age, BMI, or polyp size, which are concurrent with previous studies [18, 19].

There are some limitations in this study. For example, because this was a retrospective study, we could not take into account enough factors affecting the recurrence of EPs, and other concealed factors need to be explored. Furthermore, CE treated with antibiotics cohort was not included in our study, we do not know whether the effect of CE on the recurrence of EPs can be eliminated when treated with antibiotics.

In conclusion, this study demonstrated that CE was a harmful factor for the recurrence of EPs in premenopausal women after hysteroscopic polypectomy. Thus, routine screening for CE during hysteroscopic polypectomy was needed. Frequent monitoring was needed for multiple EPs as the number of EPs also contributed to polyp recurrence. The role of CE in the recurrence of EPs and whether cured CE can provide prevention to eliminate the harmful effect need to be further confirmed by prospective trials with larger sample sizes.